Patents by Inventor Tse-I Lin

Tse-I Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to enhance the transcription regulation of SUPT4H on genes containing repetitive nucleotide sequences
    Patent number: 11891601
    Abstract: The present invention provides a method of modulating the expression of a gene containing expanded nucleotide repeats in a cell, comprising: inhibiting the biological activity of SPT4 or SUPT4H; and regulating the formation of R-loops. The inhibition step can effectively reduce the expression of the gene containing the expanded nucleotide repeats and the regulatory step can further enhance the inhibition step. The inhibition step and the regulation step are for the purpose of regulating gene expression by interfering the capacity of RNA polymerase II transcribing over a DNA template with lengthy nucleotide repeats.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: February 6, 2024
    Assignee: NATIONAL YANG MING CHIAO TUNG UNIVERSITY
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tse-I Lin, Yun-Yun Wu, Stanley N. Cohen
  • Method to enhance the transcription regulation of SUPT4H on genes containing repetitive nucleotide sequences
    Publication number: 20210040479
    Abstract: The present invention provides a method of modulating the expression of a gene containing expanded nucleotide repeats in a cell, comprising: inhibiting the biological activity of SPT4 or SUPT4H; and regulating the formation of R-loops. The inhibition step can effectively reduce the expression of the gene containing the expanded nucleotide repeats and the regulatory step can further enhance the inhibition step. The inhibition step and the regulation step are for the purpose of regulating gene expression by interfering the capacity of RNA polymerase II transcribing over a DNA template with lengthy nucleotide repeats.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 11, 2021
    Inventors: Tzu-Hao CHENG, Chia-Rung LIU, Tse-I LIN, Yun-Yun WU, Stanley N. COHEN
  • Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C
    Patent number: 9987277
    Abstract: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: June 5, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Oliver Lenz, Tse-I Lin, Kenneth Simmen
  • Pteridines useful as HCV inhibitors and methods for the preparation thereof
    Patent number: 9951075
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 24, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF
    Publication number: 20170275288
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Pteridines useful as HCV inhibitors and methods for the preparation thereof
    Patent number: 9708328
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 18, 2017
    Assignee: Janssen Sciences Ireland UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
    Patent number: 9427440
    Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 30, 2016
    Assignee: Janssen Sciences Ireland UC
    Inventors: Sandrine Marie Helene Vendeville, Pierre Jean-Marie Bernard Raboisson, Tse-I Lin, Abdellah Tahri, Katie Ingrid Eduard Amssoms
  • Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
    Publication number: 20160158238
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominque Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
    Publication number: 20160159803
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Pteridines useful as HCV inhibitors and methods for the preparation thereof
    Patent number: 9290502
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 22, 2016
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
    Patent number: 8921355
    Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: December 30, 2014
    Assignee: Janssen R & D Ireland
    Inventors: Sandrine Marie Helene Vendeville, Pierre Jean-Marie Bernard Raboisson, Tse-I Lin, Abdellah Tahri, Katie Ingrid Eduard Amssoms
  • Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
    Publication number: 20140094468
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: Tibotec Pharmaceuticals Ltd.
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique LouisNestorGhislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
    Publication number: 20130028865
    Abstract: The present invention relates to a combination of a macrocyclic HCV protease inhibitor, a macrocyclic non-nucleoside HCV polymerase inhibitor and a nucleoside HCV polymerase inhibitor.
    Type: Application
    Filed: April 13, 2011
    Publication date: January 31, 2013
    Applicants: MEDIVIR AB, JANSSEN PHARMACEUTICALS, INC.
    Inventors: Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson
  • Fused bicyclic inhibitors of HCV
    Patent number: 8030318
    Abstract: Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: October 4, 2011
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson, Sarvajit Chakravarty, Barry Patrick Hart
  • Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
    Patent number: 8022077
    Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines of formula (I) wherein L, R1, R2 and R3 have specific meaning. The present invention also relates to the use of the compounds of formula (I) as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds of formula (I) per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: September 20, 2011
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson
  • Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside
    Publication number: 20110171174
    Abstract: The present invention relates to a synergistic combination of the compound of formula I: or a pharmaceutically acceptable salt thereof, and the compound of formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2009
    Publication date: July 14, 2011
    Applicant: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.
    Inventors: Tse-I Lin, Oliver Lenz
  • HCV inhibiting bi-cyclic pyrimidines
    Patent number: 7977342
    Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: July 12, 2011
    Assignee: Tibotec-Virco Virology BVBA
    Inventors: Kenneth Alan Simmen, Tse-I Lin, Oliver Lenz, Dominique Louis Nestor Ghislain Surleraux, Pierre Jean-Marie Bernard Raboisson
  • 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
    Patent number: 7960387
    Abstract: The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: June 14, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Gerald Kleymann, Thomas Lampe, Susanne Nikolic, Jürgen Reefschläger, Rudolf Schohe-Loop, Frank Süβmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jörg Keldenich, Thomas Krämer, Peter Nell, Tse-I Lin
  • Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
    Patent number: 7709491
    Abstract: The invention relates to substituted quinazolines and to methods for the production thereof, in addition to the use thereof in the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, especially against cytomegaloviruses.
    Type: Grant
    Filed: October 25, 2003
    Date of Patent: May 4, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tobias Wunberg, Judith Baumeister, Mario Jeske, Susanne Nikolic, Frank Süβmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jörg Keldenich, Dieter Lang, Tse-I Lin
  • CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS
    Publication number: 20090247523
    Abstract: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.
    Type: Application
    Filed: October 4, 2007
    Publication date: October 1, 2009
    Inventors: Pierre Jean-Marie Bernard Raboisson, Oliver Lenz, Tse-I Lin, Kenneth Simmen